• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

    3/6/23 7:00:00 AM ET
    $ABT
    $KRYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABT alert in real time by email

    PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors.

    "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives."

    "After watching the strong execution of Krystal over the past years, I am excited to join the Company's Board of Directors at this pivotal stage for the Company," said Ms. Mazzacco. "I look forward to working with the other board members and the leadership team to continue Krystal's commercialization preparedness while advancing the rest of the pipeline and transform lives with treatments in genetic rare diseases."

    Ms. Mazzacco was Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories (NYSE:ABT) holding global senior operational and strategic leadership roles, including, most recently, Vice President, Global Commercial Operations, Abbott Vision Division. Ms. Mazzacco is a Member of the Supervisory Board and Remuneration & Nomination Committee of Servier, a privately owned global pharmaceutical company. Ms. Mazzacco holds a BSE, Engineering, Option Biotechnology from the University of Compiègne in France.

    About Krystal Biotech, Inc.

    Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company's wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.

    CONTACT:

    Investors and Media                                                                

    Meg Dodge                                                      

    Krystal Biotech                                                    

    [email protected]                                             



    Primary Logo

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $KRYS

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Krystal Biotech Inc.
    $KRYS
    3/5/2025$245.00Buy
    Jefferies
    Abbott Laboratories
    $ABT
    10/8/2024$130.00Outperform
    Oppenheimer
    Abbott Laboratories
    $ABT
    9/19/2024$131.00Overweight
    Piper Sandler
    Krystal Biotech Inc.
    $KRYS
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    Abbott Laboratories
    $ABT
    7/30/2024Buy → Hold
    Edward Jones
    More analyst ratings

    $ABT
    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

    PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 3, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53113. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbi

    10/21/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

    Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increaseABBOTT PARK, Ill., Oct. 15, 2025  /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2025. Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.Third-quarter GAAP diluted EPS of $0.94 and ad

    10/15/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

    PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 (HSV-1) viral vector used in the Company's redosable eye drop gene therapy KB801, currently under evaluation in a randomized placebo controlled trial for the treatment of neurotrophic keratitis (NK). "Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene delivery plat

    10/14/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    10/2/25 5:02:53 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    10/2/25 4:50:38 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gonzalez Patricia Paola

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    10/2/25 4:42:16 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $KRYS
    SEC Filings

    View All

    Krystal Biotech Inc. filed SEC Form 8-K: Other Events

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    10/22/25 8:01:41 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    10/15/25 7:33:48 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    8/4/25 7:09:44 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $KRYS
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

    PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

    4/7/25 4:30:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    $KRYS
    Financials

    Live finance-specific insights

    View All

    Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

    PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 3, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53113. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbi

    10/21/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

    Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increaseABBOTT PARK, Ill., Oct. 15, 2025  /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2025. Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.Third-quarter GAAP diluted EPS of $0.94 and ad

    10/15/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Hosts Conference Call for Third-Quarter Earnings

    ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in dia

    9/24/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/12/24 10:32:12 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Krystal Biotech Inc.

    SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

    10/16/24 12:28:49 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care